DII235

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Cardiovascular risk reduction in participants with elevated Lp(a)Lipoprotein Disorder

Phase 2

A Study of DII235 in Adults With Elevated Lipoprotein(a)

Active, not recruitingNCT07235046

Novartis PharmaceuticalsLipoprotein Disorder

Start: 2025-12-02End: 2028-04-25Updated: 2026-08-07

A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)

RecruitingCTIS2025-521912-21-00

Novartis Pharma AGCardiovascular risk reduction in participants with elevated Lp(a)

Start: 2026-01-26Target: 72Updated: 2026-01-13